![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Vermillion Awarded FDA Clearance for Overa
Vermillion Awarded FDA Clearance for Overa
Austin, Texas-based Vermillion has earned FDA clearance for its blood test Overa — dubbed a successor to its OVA1 — for identifying ovarian cancer risk.
The test is intended for use in combination with clinical and imaging assessment before surgery in women with a pelvic mass, the company says.
Overa operates on a Roche Cobas 6000 platform. Further, it swaps two biomarkers from the original test out for human epididymal protein 4 and a follicle stimulating hormone to enhance specificity and minimize the need to determine menopausal status. — Anisa Jibrell
Upcoming Events
-
21Oct